Company: DMAAR
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001213900-25-026240
Chunk: 885

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 9B
Chunk 885
---
 rights will expire worthless.

Representative Shares — The
Company issued to Clear Street LLC, the representative of the underwriters in the Initial Public Offering, 230,000 ordinary shares (the
“representative shares”) at the time of the consummation of Initial Public Offering and exercise of the over-allotment option.
The holders of the representative shares have agreed (i) that they will not transfer, assign or sell any such shares without our prior
consent until the completion of the initial Business Combination, (ii) to waive their redemption rights (or right to participate in any
tender offer) with respect to such shares in connection with the completion of the initial Business Combination and (iii) to waive their
rights to liquidating distributions from the Trust Account with respect to such shares if the Company fails to complete its initial Business
Combination within 15 months from the closing of the Initial Public Offering (or up to 21 months from the closing if the Company extends
the period of time to consummate a Business Combination).

The representative shares have been deemed compensation
by FINRA and are therefore subject to a lock-up for a period of 180 days immediately following the commencement of sales of the Initial
Public Offering pursuant to Rule 5110(e)(1) of FINRA’s NASD Conduct Rules. Pursuant to FINRA Rule 5110(e)(1), these securities will
not be the subject of any hedging, short sale, derivative, put or call transaction that would result in the economic disposition of the
securities by any person for a period of 180 days immediately following the commencement of sales of the Initial Public Offering, nor
may they be sold, transferred, assigned, pledged or hypothecated for a period of 180 days immediately following the commencement of sales
of the Initial Public Offering except to any underwriter and selected dealer participating in the Initial Public Offering and their bona
fide officers or partners.

NOTE 8 — SEGMENT INFORMATION

ASC Topic 280, “Segment Reporting,”
establishes standards for companies to report in their financial statement information about operating segments, products, services, geographic
areas, and major customers. Operating segments are defined as components of an enterprise for which separate financial information
is available that is regularly evaluated by the Company’s chief operating decision maker, or group, in deciding how to allocate
resources and assess performance.

The Company’s chief operating decision maker
has been identified as the Chief Executive Officer (“CODM”), who